News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Anika Therapeutics (ANIK) Announces Dismissal Of MONOVISC® U.S. Patent Infringement Lawsuit


3/13/2014 8:01:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid (“HA”) technology, today announced that Genzyme Corporation (plaintiff) and Anika Therapeutics, Inc. (defendant) filed a joint motion with the United States District Court for the District of Massachusetts to lift a stay and dismiss a patent infringement lawsuit concerning MONOVISC. MONOVISC, a single-injection treatment for osteoarthritis pain of the knee, received FDA PMA approval in February 2014. The court granted the parties’ motion and issued an order dismissing the litigation with prejudice on March 10, 2014. This final and unappealable order resolves the parties’ dispute and is another important milestone toward commercialization of the product in the United States.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES